[The characteristics of the hypolipidemic effect of Mevacor with its permanent multiyear use].
Changes in blood lipids were assessed in the course of 4 years in 29 patients with cholesterol (CS) levels at least 300 mg/dl (hyperlipidemia). Of these, 20 received mevacor, 9 were controls. Taking mevacor in a dose 20-40 mg/day for 6 months reduced CS in the study group by 20% and by 10% more within the next 6 months. CS in controls changed unnoticeably. Lowering of the dose to 10-20 mg/day or mevacor discontinuation at the moment CS fell to 250 mg/dl or greater did not entail a rerise of total blood CS within subsequent 4-6 months.
Lipovetskiĭ
B M
BM
D000328:Adult; D000368:Aged; D002648:Child; D004200:Diseases in Twins; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000960:Hypolipidemic Agents; D008055:Lipids; D008148:Lovastatin
Osobennosti gipolipidemicheskogo éffekta mevakora pri ego permanentnom mnogoletnem primenenii.